Israel - English - Ministry of Health

inovamed ltd - ondansetron as hydrochloride dihydrate 2 mg / 1 ml - solution for injection - ondansetron - adults:ondansetron inovamed is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. ondansetron inovamed is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:ondansetron inovamed is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.

Israel - English - Ministry of Health

inovamed ltd - bicalutamide - film coated tablets - bicalutamide 50 mg - bicalutamide - bicalutamide - for the treatment of advanced prostate cancer in combination with luteinising hormone-releasing hormone (lhrh) analog therapy or surgical castration.

Israel - English - Ministry of Health

inovamed ltd - bicalutamide - film coated tablets - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0), bicalutamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable

Israel - English - Ministry of Health

inovamed ltd - anastrozole - film coated tablets - anastrozole 1 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Israel - English - Ministry of Health

inovamed ltd - exemestane 25 mg - film coated tablets - exemestane - exemestane inovamed is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane inovamed is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. exemestane inovamed is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Israel - English - Ministry of Health

inovamed ltd - montelukast as sodium 5 mg - chewable tablets - montelukast - montelukast inovamed is indicated in pediatric patients 6 to 14 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction.montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 6 to 14 years of age.

Israel - English - Ministry of Health

inovamed ltd - montelukast as sodium 4 mg - chewable tablets - montelukast - montelukast inovamed is indicated in pediatric patients 2 to 5 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 to 5 years of age.

Israel - English - Ministry of Health

inovamed ltd - montelukast as sodium 10 mg - film coated tablets - montelukast - montelukast inovamed is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction.montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and adolescents 15 years of age and older.

Israel - English - Ministry of Health

inovamed ltd - bortezomib - powder for solution for injection - bortezomib 3.5 mg - bortezomib - bortezomib inovamed is indicated for the treatment of patients with multiple myeloma.bortezomib inovamed is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib inovamed in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Israel - English - Ministry of Health

inovamed ltd - lamivudine; zidovudine - film coated tablets - lamivudine 150 mg; zidovudine 300 mg - zidovudine - lamivudine & zidovudine inovamed 150 mg / 300 mg is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection.